These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 18570862)
1. [Metastatic gastroenteropancreatic neuroendocrine tumours: 111In-pentetreotide and PET-FDG imaging]. Serra Arbeloa P; Lancha Hernández C Rev Esp Med Nucl; 2008; 27(3):199-201. PubMed ID: 18570862 [TBL] [Abstract][Full Text] [Related]
2. 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy. Yüksel M; Eziddin S; Wardelmann E; Biersack HJ Rev Esp Med Nucl; 2006 Sep; 25(5):316-9. PubMed ID: 17173778 [TBL] [Abstract][Full Text] [Related]
3. [111In-pentetreotide in the study of tumors expressing somatostatin receptors]. Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660 [TBL] [Abstract][Full Text] [Related]
6. Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors. Kubota K; Okasaki M; Minamimoto R; Miyata Y; Morooka M; Nakajima K; Sato T Ann Nucl Med; 2014 Dec; 28(10):1004-10. PubMed ID: 25179521 [TBL] [Abstract][Full Text] [Related]
7. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878 [TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. Jamar F; Fiasse R; Leners N; Pauwels S J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439 [TBL] [Abstract][Full Text] [Related]
9. Preferential localization of regional metastases from gastroenteropancreatic endocrine tumors with somatostatin-receptor scintigraphy. MacGillivray DC; Mumtaz MA; Kurtzman SH; Spencer RP; Weiner RE; Malchoff CD Arch Surg; 1996 Dec; 131(12):1338-42. PubMed ID: 8956777 [TBL] [Abstract][Full Text] [Related]
10. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743 [TBL] [Abstract][Full Text] [Related]
12. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas]. Banzo J; Abós MD; Prats E; García F; Razola P Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088 [No Abstract] [Full Text] [Related]
13. The Supporting Role of (18)FDG-PET in Patients with Neuroendocrine Tumors. Howe JR Ann Surg Oncol; 2015 Jul; 22(7):2107-9. PubMed ID: 25777088 [No Abstract] [Full Text] [Related]
14. [Scintigraphy atlas of somatostatin receptors in neuroendocrine tumors of the pancreas and carcinoid tumors]. Banzo J; Prats E; Razola P; García S; Alonso V; Velilla J; Freile E; Benito JL; García F; Ubieto MA; Tardín L; Abós MD Rev Esp Med Nucl; 2005; 24(4):278-92. PubMed ID: 16122413 [No Abstract] [Full Text] [Related]
15. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Chiti A; Briganti V; Fanti S; Monetti N; Masi R; Bombardieri E Q J Nucl Med; 2000 Mar; 44(1):42-9. PubMed ID: 10932600 [TBL] [Abstract][Full Text] [Related]
16. Nuclear medicine imaging of neuroendocrine tumours. Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353 [TBL] [Abstract][Full Text] [Related]
17. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063 [TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine tumors and somatostatin: imaging techniques. de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862 [TBL] [Abstract][Full Text] [Related]
19. Whole body and tomographic scan with 111In-pentetreotide: preliminary data. Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769 [TBL] [Abstract][Full Text] [Related]
20. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours. Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]